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Abstract
Background: Genetics plays an important role in the susceptibility to sporadic colorectal cancer (CRC). In the last
10 years genome-wide association studies (GWAS) have identified over 40 independent low penetrance polymorphic
variants. However, these loci only explain around 1‑4% of CRC heritability, highlighting the dire need of identifying
novel risk loci. In this study, we focused our attention on the genetic variability of the TAS2R16 gene, encoding for one
of the bitter taste receptors that selectively binds to salicin, a natural antipyretic that resembles aspirin. Given
the importance of inflammation in CRC, we tested whether polymorphic variants in this gene could affect the
risk of developing this neoplasia hypothesizing a role of TAS2R16 in modulating chronic inflammation within the gut.
Methods: We performed an association study using 6 tagging SNPs, (rs860170, rs978739, rs1357949, rs1525489,
rs6466849, rs10268496) that cover all TAS2R16 genetic variability. The study was carried out on 1902 CRC cases
and 1532 control individuals from four European countries.
Results: We did not find any statistically significant association between risk of developing CRC and selected
SNPs. However, after stratification by histology (colon vs. rectum) we found that rs1525489 was associated
with increased risk of rectal cancer with a (Ptrend of = 0.0071).
Conclusions: Our data suggest that polymorphisms within TAS2R16 gene do not have a strong influence on
colon cancer susceptibility, but a possible role in rectal cancer should be further evaluated in larger cohorts.
Keywords: Taste receptors, TAS2R16, Polymorphisms, Colon cancer, Rectal cancer, Colorectal cancer, Cancer
risk, Genetic association study
Background
Colorectal cancer (CRC) is the third most commonly diag-
nosed cancer worldwide [1]. Several environmental/life
style risk factors have been identified for CRC, such as
obesity, sedentary behavior, high red meat consumption,
high intake of hyper caloric foods, diets rich in fat and poor
in fiber, tobacco smoking, alcohol consumption and dia-
betes [2]. In addition gut inflammation, due to chronic con-
ditions such as ulcerative colitis and Crohn’s disease, is an
established risk factor [2]. Also genetics is hypothesized to
play an important role for the sporadic form. In the last
10 years genome-wide association studies (GWAS) have
identified over 40 independent low penetrance polymorphic
variants [3]. Besides GWAS, an overwhelming number of
hypothesis-driven studies carried out on specific candidate
genes highlighted variants belonging to multiple pathways
to be connected to CRC risk. The majority of the studies
focused on SNPs within DNA repair genes [4], xenobiotic
metabolism and transport genes [5–14], inflammatory re-
sponse genes [15–17], hormone metabolisms [18, 19] and
more recently miRNAs [20, 21]. Our group and others have
also analyzed the possible involvement of taste receptor
genes in CRC risk [22–24]. In the human genome, there
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are 25 functional genes and 11 pseudogenes belonging to
the TAS2Rs gene family. It has already been ascertained that
polymorphic variants in these genes are responsible for the
variability observed in several human phenotypes and life
habits such as alcohol consumption [25, 26], and nicotine
dependence [27]. However, taste receptors seem to have
also less obvious functions. In fact taste receptors certainly
do not only have a role in taste perception, as documented
by their ectopic expression in a variety of extra-oral tissues
including gut [28–31]. In this study we focused our atten-
tion on the genetic variability of the TAS2R16 gene whose
encoded receptor selectively binds to salicin [32], a natural
anti-inflammatory and analgesic agent extracted from wil-
low bark and resembling aspirin [33]. Given the similarities
between salicin and aspirin it is reasonable to postulate that
variants within the TAS2R16 gene could affect the receptor
activity following its binding with ligands such as salicin or
aspirin. In particular, aspirin intake is an established factor
reducing the risk to develop CRC. In fact, there are evi-
dences from case-control and cohort studies indicating
benefit from long term use of aspirin at low dose in colo-
rectal cancer chemoprevention [34]. This effect could be
elicited through an anti-inflammatory activity or to the
binding to specific receptors in the gut. Furthermore, there
are indications that regular use of aspirin is associated with
improved survival for patients with colorectal cancer [35].
The hypothesis is corroborated by a previous study (Camp-
bell and colleagues) conducted on two different African
populations, describing that the polymorphic variant
rs846664 within TAS2R16 confers different sensitivities to
salicin [36]. Unfortunately, this finding could not be repli-
cated among Caucasians since this SNP is monomorphic in
this population. However, according to this base of know-
ledge, it could be hypothesized that TAS2R16 could modu-
late chronic inflammation in the gut. Alternatively, the
receptor, upon binding with its natural ligands, could affect
the individual risk of cancer with mechanisms similar to
those observed following a long term aspirin intake. Thus,
in the present work we tested whether polymorphic vari-
ants within TAS2R16 could affect the risk of developing
CRC. The study was carried out in a large cohort of Euro-
pean individuals.
Methods
Study population
A total of 2252 CRC case subjects and 1630 controls were
collected in four European countries (Czech Republic,
Italy, Lithuania and Spain). CRC patients had histological
verification of colorectal adenocarcinoma. Controls were
collected in the same hospitals and in the same time frame
as the cases among hospitalized individuals without neo-
plastic diseases. A more detailed description of the sam-
pling and collection methods has been provided elsewhere
[9, 37–39]. For the cases we collected information about
gender, age at diagnosis, tumor localization (colon or rec-
tum), while for the controls we have information on gen-
der and age at sampling.
SNPs selection
We used tagging SNPs to cover all the common genetic
variability of TAS2R16. We selected the gene region and
added 4 k base pairs on the 5 prime and 3 prime direc-
tions. According to HapMap 3 database, within the se-
lected region there are 24 known common SNPs with a
MAF > 0.05 among Caucasians. Using the software Hap-
loview [40] we selected six tagging SNPs by setting the
LD threshold at r2 ≥ 0.8. The final selection of the SNPs
resulted in rs860170, rs978739, rs1357949, rs1525489,
rs6466849, and rs10268496 covering 87% of the com-
mon genetic variability.
Sample preparation and genotyping
DNA was extracted from whole blood. Samples were
kept frozen until used. Genotyping was performed on
384 well plates using the KASP (LGC, Teddington, UK)
and TaqMan (Thermo Fisher, Waltham, MA USA) geno-
typing chemistry. In each plate there was DNA from
cases and controls in order to avoid bias due to genotyp-
ing. We included a mean of 15 duplicated samples for
plate to be used as quality controls. After the PCR the
plates were “read” via the spectrophotometer Fluostar
Omega (Ω) (BMG.LABTECH®) and genotyping calls
were done using the KlusterCaller software (LGC Group
Teddington, UK).
Statistical analysis
The observed genotype frequencies of all SNPs were
tested for deviation from Hardy–Weinberg equilibrium
(HWE) in controls. The association between the geno-
types of all polymorphisms and CRC risk was estimated
using an unconditional logistic regression computing odds
ratios (OR), 95% confidence intervals (95% CIs) and P-
values. The common allele among the controls was
assigned as the reference category and the co-dominant
inheritance model was assessed. All analyses were adjusted
for age (at diagnosis for cases and at sampling for con-
trols), gender and country origin. We also performed
stratified analyses for country of origin and tumor site.
The significance level in each test was adjusted according
to the Bonferroni’s correction, namely adjusted P = α/
number of individual tests (0.05/6 = 0.008).
Bioinformatic tools
We carried out bioinformatic analyses to assess the pos-
sible functional effect of the studied polymorphisms, for
example to detect if the nucleotide sequences of the
polymorphisms are targets of transcription factors or if
they are situated in DNase sensitivity region. Specifically
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we have used RegulomeDB V1.1 [41] and Haploreg V4.1
[42]; to test whether the polymorphisms could have a
known regulatory impact. Additionally, we used the data
available in the GTEx project V6 to identify expression
of quantitative trait loci (eQTLs) [43].
Results
Data filtering and quality control
We examined 6 SNPs belonging to the TAS2R16 gene to
assess their possible role in the risk of developing CRC.
We have genotyped up to 3882 individuals (2252 CRC
cases and 1630 controls) enrolled in the Czech Republic,
Lithuania, Italy and Spain. The distributions of the geno-
type frequencies for all the variants included in the study
were in accordance with HWE. Four hundred forty-eight
(448) subjects (346 CRC cases 102 controls) for which
we did not have covariates data or that did not pass
quality control (call rate < 75%) were removed from sub-
sequent analyses, leaving a total of 3434 subjects (1902
CRC cases and 1532 controls) for statistical analysis. All
the relevant characteristics of the population used in the
analyses are shown in Table 1. The average SNP call rate
was 96.24% with a minimum of 98.16% (rs1525489) and
a maximum of 99.66% (rs10268496). The analysis of the
samples duplicated for quality control showed a con-
cordance greater than 99%. All the frequencies, call rate
and HWE values of each polymorphism are reported in
Additional file 1: Table S1.
Effect of SNPs on colorectal cancer risk
Overall, we did not observe any statistically significant as-
sociation between selected SNPs and risk of CRC. The
polymorphism with the lowest p-value was rs1525489
showing a p-trend of P = 0.084. Following the stratifica-
tion by tumor site (colon / rectum) we found that
rs1525489 showed a marginal/borderline significance with
increased risk of rectal cancer at nominal level of
(Ptrend = 0.0071), while the associations between the SNPs
and colon cancer were similar to those considering the
two strata together (Table 2). However, performing a case-
case analysis (colon vs. rectum) we did not observe any
heterogeneity. When stratifying for country of origin we
obtained one marginally significant value. In the Lithu-
anian case control study subjects the minor (C) allele of
rs1525489 was associated with an increased risk of devel-
oping CRC with a nominal Ptrend = 0.047. We observed
the same trend also in the Spanish sub-population
(P = 0.051). The stratified analyses are reported in Add-
itional file 2: Table S2, Additional file 3: Table S3, Add-
itional file 4: Table S4, and Additional file 5: Table S5.
Bioinformatic analysis
We used three bioinformatic tools to identify possible
functional properties of rs1525489, the SNP showing the
best results from a statistical point of view. RegulomeDB
showed a score of six (which means minimal binding
evidence). Using HaploReg we did not observe any po-
tentially relevant data. GTEx database did not show any
statistically significant eQTLs between the SNP and
nearby genes in any of the tissues present in the
database.
Discussion
To further expand our knowledge on CRC genetic sus-
ceptibility we investigated whether polymorphic variants
within TAS2R16 could have a role in the etiology of the
disease. Our hypothesis finds its rationale on several epi-
demiologic evidences that polymorphic variants within
taste receptor genes could be associated with risk of can-
cer development. For instance TAS2R38 SNPs were
found to be associated with risk of developing CRC in
two different populations of Caucasian origin [23], while
SNPs within TAS2R38 and TAS1Rs were associated with
increased risk of gastric cancer [44, 45]. In this study we
examined the genetic variability of TAS2R16 gene be-
cause the receptor binds different compounds including
salicin, a natural anti-inflammatory substance which is
very similar to aspirin [32, 33]. One of the strongest risk
factors for CRC is represented by chronic inflammation
especially arisen from diseases that trigger a continuous
inflammatory responses such as ulcerative colitis and
Crohn’s disease [2]. Aspirin treatment reduces the risk
of CRC [2] and therefore genetic variants that modulate
the efficiency or the expression of the receptor may play
a role in CRC development. Since polymorphisms in
taste genes are generally functional as reflected in their
effect in a multitude of phenotypes, it is reasonable to
hypothesize a possible link between TAS2R16 allelic
Table 1 Population in study
Country of
origin
Colorectal Cancer Cases Controls
Males Females Total Mean Age Males Females Total Mean Age
Czech Republic 588 400 988 61.92 393 296 689 54.87
Lithuania 102 76 178 67.04 91 92 183 57.29
Italy 179 142 321 65.97 252 94 346 51.94
Spain 248 167 415 66.35 166 148 314 65.34
Total 1117 785 1902 64.09 902 630 1532 56.69
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variants and CRC risk. To perform our analysis 6 SNPs
tagging the common variants present in the region of
the gene under examination were chosen. The selection
was mainly based on linkage disequilibrium scores be-
tween all the variants of the region. Our results seem to
suggest no association between the selected polymorph-
ism and risk of developing CRC. The signal closest to
the significance threshold of P < 0.05 was observed for
rs1525489. For this SNP stratifying the analysis for coun-
try of origin we found in the Lithuanian and in the
Spanish sub-populations a tendency for individuals with
at least 1 C allele of the rs1525489 polymorphism to
have and increased risk of developing CRC (P 0.047 and
P = 0.051, respectively). However, these associations
were not statistically significant following Bonferroni’s
correction. A possible explanation for this association is
that this SNP interact with a lifestyle factor or a dietary
habit a factor that we do not account for in the analysis.
However, this difference maybe just due to statistical
fluctuations. Schembre and colleagues have performed a
study investigating two TAS2R16 polymorphic variants
(rs846672 and rs846664) in relation to the risk of devel-
oping colorectal adenoma [24]. Even though the study is
rather small (914 cases of three different ethnic groups)
Table 2 Association between colorectal cancer risk and SNPs in the TAS2R16 region stratified by histology
SNP Alleles
(Major/
minor)
Site Case/Controla MM vs
Mmb
P
value
MM vs
mmb
P
value
MM vs Mm
+mmb
P
value
MM + Mm
vs mmb
P
value
P
trendMM Mm mm
rs860170 A/G All 785/653 846/
681
245/
184
1.04(0.9–
1.22)
0.57 1.05(0.83–
1.32)
0.69 1.05(0.9–
1.21)
0.55 1.03(0.83–
1.27)
0.82 0.37
Colon 447/653 487/
681
141/
184
1.03(0.87–
1.23)
0.73 1.07(0.82–
1.4)
0.52 1.04(0.88–
1.23)
0.64 1.06(0.82–
1.35)
0.67 0.37
Rectum 231/653 256/
681
68/
184
1.06(0.85–
1.32)
0.61 1.02(0.74–
1.43)
0.89 1.05(0.85–
1.29)
0.64 0.99(0.73–
1.36)
0.97 0.65
rs978739 A/G All 830/693 777/
678
182/
156
0.97(0.83–
1.13)
0.67 0.98(0.77–
1.26)
0.89 0.97(0.84–
1.12)
0.68 1(0.79–1.27) 0.99 0.65
Colon 487/693 422/
678
97/
156
0.9(0.75–
1.07)
0.22 0.88(0.65–
1.17)
0.37 0.89(0.75–
1.05)
0.18 0.92(0.7–
1.22)
0.58 0.18
Rectum 240/693 222/
678
71/
156
0.97(0.78–
1.22)
0.82 1.36(0.97–
1.9)
0.08 1.04(0.85–
1.29)
0.68 1.37(1–1.89) 0.05 0.30
rs1357949 T/C All 927/719 761/
659
180/
145
0.91(0.78–
1.05)
0.20 0.95(0.74–
1.23)
0.71 0.91(0.79–
1.06)
0.22 1(0.78–1.27) 0.99 0.31
Colon 512/719 443/
659
110/
145
0.97(0.81–
1.15)
0.72 1.09(0.82–
1.46)
0.54 0.99(0.84–
1.17)
0.92 1.11(0.84–
1.46)
0.46 0.98
Rectum 292/719 211/
659
50/
145
0.78(0.63–
0.97)
0.03 0.82(0.57–
1.19)
0.30 0.79(0.64–
0.97)
0.02 0.92(0.65–
1.32)
0.66 0.06
rs1525489 T/C All 1728/
956
145/
62
1/0 1.24(0.88–
1.73)
0.22 - - 1.22(0.88–
1.70)
0.23 - - 0.08
Colon 992/956 77/62 0/0 1.22(0.83–
1.8)
0.30 - - 1.22(0.83–
1.8)
0.30 - - 0.31
Rectum 505/956 53/62 1/0 1.59(1.03–
2.43)
0.03 - - 1.62(1.06–
2.47)
0.03 - - 0.007
rs6466849 G/A All 1276/
1024
524/
452
62/52 0.97(0.83–
1.14)
0.75 1.01(0.68–
1.51)
0.95 0.98(0.84–
1.14)
0.78 1.02(0.69–
1.51)
0.92 0.40
Colon 748/
1024
284/
452
36/52 0.88(0.73–
1.05)
0.16 0.97(0.61–
1.53)
0.88 0.88(0.74–
1.06)
0.18 1(0.64–1.58) 0.99 0.16
Rectum 376/
1024
156/
452
22/52 1(0.8–1.26) 0.97 1.25(0.73–
2.15)
0.42 1.03(0.83–
1.28)
0.79 1.25(0.73–
2.13)
0.42 0.92
rs10268496 T/G All 1200/
951
596/
510
100/
70
0.92(0.79–
1.07)
0.28 1.07(0.77–
1.49)
0.70 0.94(0.81–
1.08)
0.38 1.1(0.79–
1.53)
0.57 0.81
Colon 678/951 342/
510
62/70 0.94(0.79–
1.12)
0.49 1.18(0.81–
1.71)
0.39 0.97(0.82–
1.15)
0.72 1.2(0.83–
1.74)
0.33 0.79
Rectum 364/951 175/
510
25/70 0.88(0.7–
1.09)
0.24 0.86(0.53–
1.41)
0.55 0.87(0.71–
1.08)
0.21 0.9(0.55–
1.46)
0.67 0.37
aNumbers may not add up 100% to genotyping failure, covariate missing values or DNA depletion
bMM vs Mm = Common homozygous carriers vs heterozygous; MM vs mm = Common homozygous vs rare homozygous; MM vs Mm + mm = Common
homozygous vs heterozygous + rare homozygous (Dominant Model); MM + Mm vs mm = Common homozygous + heterozygous vs rare homozygous. Odds Ratio
(95% confidence interval).All analysis are adjusted for age, gender and country of origin
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their results are concordant with ours, suggesting an
overall no effect of the two variants in the disease. The
rs846664 SNP is monomorphic in Caucasian and there-
fore was not typed in our study while rs846672 is in
complete LD with rs860170 that was used in the present
study (r2 = 1 in European Hapmap Ceu). When analyz-
ing separately colon and rectum, we observed an associ-
ation between the minor allele of the rs1525489 and an
increased risk of developing specifically rectal cancer.
This association was showed to have a marginal/border-
line statistically significance also after Bonferroni’s cor-
rection (P = 0.0071). However, this finding must be
taken with caution since it is the result of a stratified
analysis, on a limited sample size, and it is also difficult
to explain from a biological point of view. In fact, the
bioinformatics tools did not reveal any possible func-
tional effect for this SNP nor for the variants in LD with
it. We acknowledge that the present study has several
limitations. We could not collect information on aspirin
use and therefore we could not analyze any possible
interaction with the SNP analyzed. Moreover, cases and
controls are not individually matched for age and gen-
der, however we have adjusted all the analyses for these
two variables to minimize their possible effect. We had a
power greater than 80% (considering an alpha of 0.05/
6 = 0.008) to find an association with an OR of 1.25 or
higher for all the SNPs in analysis with the exception of
rs1525489 that had a low MAF and for which we had
the power to find OR greater than 1.53. An OR of 1.25
is compatible with the ORs found by GWAS in CRC [3].
Using a tagging approach, we have covered most of the
common variability of the gene region excluding the
possibility of having missed an association with a com-
mon but un-typed variant.
Conclusions
Thus, although we have to be very cautious with the re-
sults, our data suggest that polymorphisms of the
TAS2R16 gene do not have a strong influence on colon
cancer susceptibility, but that the study should be repli-
cated in large cohorts to better evaluate the effect of
rs1525489 on the risk of rectal cancer.
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